Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Salute | Ricerca medica e biotecnologica | 108,86 Mrd USD | -229,2x | 1,93 | 422 USD | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21,7% Rialzo | Fai l’upgrade a Pro+ | |
Regeneron Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 73,32 Mrd USD | 15,9x | 1,05 | 681,58 USD | -1,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 46,4% Rialzo | Fai l’upgrade a Pro+ | |
Lonza Group AG | OTC Markets | Salute | Ricerca medica e biotecnologica | 43,96 Mrd USD | 67,6x | -1,45 | 60,71 USD | 1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 17,6% Rialzo | Fai l’upgrade a Pro+ | |
argenx ADR | NASDAQ | Salute | Ricerca medica e biotecnologica | 39,53 Mrd USD | -966,5x | -11,8 | 640,52 USD | -2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 6,6% Rialzo | Fai l’upgrade a Pro+ | |
IQVIA Holdings | NYSE | Salute | Ricerca medica e biotecnologica | 35,80 Mrd USD | 25,5x | 0,94 | 197,36 USD | -0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 27,7% Rialzo | Fai l’upgrade a Pro+ | |
BioNTech | NASDAQ | Salute | Ricerca medica e biotecnologica | 26,93 Mrd USD | -56,7x | 0,53 | 111,93 USD | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 18,8% Rialzo | Fai l’upgrade a Pro+ | |
BeiGene ADS | NASDAQ | Salute | Ricerca medica e biotecnologica | 21,88 Mrd USD | -26x | -1,4 | 205,34 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 42,8% Rialzo | Fai l’upgrade a Pro+ | |
ICON PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 16,36 Mrd USD | 22x | 0,54 | 198,11 USD | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 33,4% Rialzo | Fai l’upgrade a Pro+ | |
United Therapeutics | NASDAQ | Salute | Ricerca medica e biotecnologica | 16,02 Mrd USD | 14,8x | 0,58 | 358,93 USD | -2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 5,2% Rialzo | Fai l’upgrade a Pro+ | |
Neurocrine | NASDAQ | Salute | Ricerca medica e biotecnologica | 14,51 Mrd USD | 37,4x | 0,38 | 143,26 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 19,1% Rialzo | Fai l’upgrade a Pro+ | |
Summit Therapeutics PLC | NASDAQ | Salute | Ricerca medica e biotecnologica | 13,41 Mrd USD | -69,2x | -0,9 | 19,03 USD | 4,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Genmab AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 13,20 Mrd USD | 20,8x | 1,51 | 20,80 USD | -2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Moderna | NASDAQ | Salute | Ricerca medica e biotecnologica | 13,11 Mrd USD | -5,8x | -0,21 | 34,06 USD | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Insmed | NASDAQ | Salute | Ricerca medica e biotecnologica | 13,05 Mrd USD | -13,2x | 2,44 | 72,51 USD | -0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 21% Rialzo | Fai l’upgrade a Pro+ | |
Bio-Techne | NASDAQ | Salute | Ricerca medica e biotecnologica | 12,04 Mrd USD | 79,3x | -2,06 | 75,83 USD | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 11,7% Rialzo | Fai l’upgrade a Pro+ | |
Sarepta | NASDAQ | Salute | Ricerca medica e biotecnologica | 11,27 Mrd USD | 93,8x | 0,85 | 118 USD | 0,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Vaxcyte | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,65 Mrd USD | -19,3x | 0,55 | 85,30 USD | -2,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medpace Holdings | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,50 Mrd USD | 28,6x | 0,88 | 337,35 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 3,5% Rialzo | Fai l’upgrade a Pro+ | |
Exelixis | NASDAQ | Salute | Ricerca medica e biotecnologica | 10,29 Mrd USD | 22,9x | 0,05 | 36,20 USD | -1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 2,6% Rialzo | Fai l’upgrade a Pro+ | |
Qiagen | NYSE | Salute | Ricerca medica e biotecnologica | 10,22 Mrd USD | 110,6x | -1,48 | 46 USD | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 8,9% Rialzo | Fai l’upgrade a Pro+ | |
EXACT Sciences | NASDAQ | Salute | Ricerca medica e biotecnologica | 9,66 Mrd USD | -44,8x | -1,9 | 51,74 USD | 2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 38,8% Rialzo | Fai l’upgrade a Pro+ | |
WuXi Biologics | OTC Markets | Salute | Ricerca medica e biotecnologica | 9,45 Mrd USD | -1,34 | 2,30 USD | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
WuXi Biologics | OTC Markets | Salute | Ricerca medica e biotecnologica | 9,45 Mrd USD | 22,9x | -1,34 | 4,64 USD | 3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Charles River Laboratories | NYSE | Salute | Ricerca medica e biotecnologica | 8,38 Mrd USD | 20,4x | -1,74 | 163,50 USD | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 26,7% Rialzo | Fai l’upgrade a Pro+ | |
Ascendis Pharma AS | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,87 Mrd USD | -17,2x | -0,58 | 128,13 USD | -2,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 48,3% Rialzo | Fai l’upgrade a Pro+ | |
Revolution Med | NASDAQ | Salute | Ricerca medica e biotecnologica | 7,43 Mrd USD | -11,3x | 1,83 | 40,29 USD | 1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Blueprint Medicines Corp | NASDAQ | Salute | Ricerca medica e biotecnologica | 7 Mrd USD | -53,3x | -0,56 | 110,05 USD | 5,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 22,2% Rialzo | Fai l’upgrade a Pro+ | |
Madrigal Pharma | NASDAQ | Salute | Ricerca medica e biotecnologica | 6,39 Mrd USD | -11,8x | 0,47 | 293,64 USD | 7,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 43,7% Rialzo | Fai l’upgrade a Pro+ | |
Legend Bio | NASDAQ | Salute | Ricerca medica e biotecnologica | 5,98 Mrd USD | -17,3x | -0,5 | 32,66 USD | 3,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Telix Pharmaceuticals ADR | NASDAQ | Salute | Ricerca medica e biotecnologica | 5,52 Mrd USD | 0,83 | 16,78 USD | 4,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 26,1% Rialzo | Fai l’upgrade a Pro+ |